09.02.2024 • News

Air Liquide and Dow Renew Supply Deal for German Site

Air Liquide and Dow renewed their industrial gas supply agreement for Dow’s chemical production site in Stade, Germany. Under the long-term agreement, Air Liquide will supply industrial gases and invest almost €40 million in modernizing its facilities to increase operational efficiency and reduce CO₂ emissions.

To achieve this, Air Liquide will modernize its existing production assets – two air separation units (ASU) and a partial oxidation unit (POX) – which will be complemented by a new CO₂ recycling solution. According to Air Liquide, this will enable a circular use of the CO₂ produced, leading to around 15% increase in energy efficiency and reducing the emissions by around 15,000 t/year, which represents 80% of direct CO₂ emissions of its site. The modernization of the assets is scheduled for completion in 2024.

Emilie Mouren-Renouard, member of Air Liquide’s executive committee and CEO of the Europe Industries Hub, said: "In view of the climate imperative, the necessary industrial transformation will require not only ground-breaking greenfield projects but also step-by-step modifications and modernization of existing plants. This is why, as part of our long term renewal of the supply agreement with Dow, we have decided to invest close to €40 million to modernize our assets in Stade. The solution implemented will apply CO₂ recycling to an existing production facility, enabling us to improve energy efficiency and reduce CO₂ emissions at the same time."

© Dow
© Dow

Company

Logo:

Dow Chemical Company

2211 HH Dow Way
48674 Midland, MI
US

Company contact







Interview

Navigating Uncertainty and Driving Innovation
Meeting Pharma’s Demand for Speed, Reliability, and Flexibility

Navigating Uncertainty and Driving Innovation

Axplora CCO Arul Ramadurai discusses navigating industry uncertainty, building strategic partnerships, and advancing flexible pharmaceutical manufacturing

Expert Insights

ADCs for Precision Cancer Therapy
Comprehensive Insights into Antibody–Drug Conjugates

ADCs for Precision Cancer Therapy

Explore how antibody-drug conjugates are reshaping precision cancer therapy and discover what it takes to successfully develop, manufacture, and scale these complex biologics.

most read

Photo

VCI Welcomes US-EU Customs Deal

The German Chemical Industry Association (VCI) welcomes the fact that Ursula von der Leyen, President of the European Commission, and US President Donald Trump have averted the danger of a trade war for the time being.